Gourarier L, Lowenstein W, Gisselbrecht M, Chauveau J M, Haas C, Durand H
Service de Médecine interne I, Hôpital Laennec, Paris.
Presse Med. 1996 Sep 21;25(27):1239-40.
Adequate dosage of sublingual buprenorphine is now recommended for substitution treatment of severe opioid dependance. We report two cases of acute discomfort, probably linked to withdrawal syndrome, after an IV injection of high doses of buprenorphine in opiate dependant patients. Data on the pharmacokinetics and neurobiochemical aspects of buprenorphine are compared with those of other opiates. A major issue of this work is a guideline for inducing substitution treatment with this "unique" partial agonist/antagonist of endorphinic receptors.